<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="198122">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511524</url>
  </required_header>
  <id_info>
    <org_study_id>CBA103679</org_study_id>
    <nct_id>NCT00511524</nct_id>
  </id_info>
  <brief_title>An Imaging Study to Investigate the Distribution of GW842166X in the Brain.</brief_title>
  <official_title>An Open Label Positron Emission Tomography (PET) Study to Investigate Brain Penetration by [11C]GW842166 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GW842166X is being developed for the treatment and management of inflammatory pain.
      GW842166X is a CB2 receptor agonist and the mechanism is not fully understood, although it
      is thought that for the anti-inflammatory action the drug is required to cross inot the
      brain from the blood. This study aims to look at if the drug crosses into the brain once
      given orally using an imaging technique called positron emission tomography.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate at which the drug crosses from plasma to brain (ki)using images from the scan</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of drug</measure>
    <time_frame>after taking the drug pre-dose, 2hr, 4hr, 6hr, 10hr, 24hr, follow-up.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Analgesia</condition>
  <condition>Inflammation</condition>
  <condition>Pain, Inflammatory</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW842166X</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male aged 50 to 80yrs inclusive at the screening visit.

          -  subjects with negative HIV and hepatitis B and C test results within 3 months of
             study start.

        Exclusion Criteria:

          -  A negative Allens test on arm to be used for arterial cannulation.

          -  Any contraindications to MRI scanning.

          -  History or presence of hepatic or renal disease.

          -  Previous involvement in PET or radiological investigations.

          -  Family history of cancer.

          -  History of claustrophobia

          -  Presence of a cardiac pacemaker or any other electronic device or ferromagnetic metal
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-753 23</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>March 15, 2012</lastchanged_date>
  <firstreceived_date>August 2, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CB2,</keyword>
  <keyword>PET</keyword>
  <keyword>brain,</keyword>
  <keyword>inflammation,</keyword>
  <keyword>analgesia,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
